Daxor Corporation Stock Nyse

Equities

DXR

US2394671034

Closed End Funds

Market Closed - Nyse 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
9.65 USD 0.00% Intraday chart for Daxor Corporation -0.92% +0.52%
Sales 2022 232K Sales 2023 163K Capitalization 46.01M
Net income 2022 5M Net income 2023 - EV / Sales 2022 174 x
Net Debt 2022 1.23M Net Debt 2023 756K EV / Sales 2023 286 x
P/E ratio 2022
7.59 x
P/E ratio 2023
164 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 38.68%
More Fundamentals * Assessed data
Dynamic Chart
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion CI
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital CI
Transcript : Daxor Corporation, 2023 Earnings Call, Mar 25, 2024
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite MT
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc. CI
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base CI
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis CI
Daxor Corporation Announces Two Significant New Customer Transactions with Daxor's BVA-100 in January 2024 CI
Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer CI
Certain Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 19-NOV-2023. CI
Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers CI
Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting CI
Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Certain Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 21-AUG-2023. CI
More news
1 week-1.03%
Current month+8.55%
1 month+11.88%
3 months+12.21%
Current year+0.52%
More quotes
1 week
9.55
Extreme 9.55
9.94
1 month
8.11
Extreme 8.11
9.94
3 years
7.11
Extreme 7.11
15.46
5 years
7.11
Extreme 7.11
24.08
10 years
3.40
Extreme 3.4001
24.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 12-12-31
Director of Finance/CFO 67 18-09-27
Chief Operating Officer - 23-02-16
Members of the board TitleAgeSince
Director/Board Member 89 88-12-31
Chief Executive Officer 54 12-12-31
Chief Tech/Sci/R&D Officer 59 -
More insiders
Date Price Change Volume
24-04-26 9.65 0.00% 503
24-04-25 9.65 -2.92% 1,850
24-04-24 9.94 +1.43% 1,010
24-04-23 9.8 +0.10% 532
24-04-22 9.79 +0.41% 477

Delayed Quote Nyse, April 26, 2024 at 04:30 pm EDT

More quotes
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.65 USD
Average target price
23.25 USD
Spread / Average Target
+140.93%
Consensus

Chiffre d''affaires - Rate of surprise